Business
Zimmer Biomet Announces Japan PMDA Approval of World's First Iodine-Treated Total Hip Replacement System
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the Pharmaceutical and Medical Devices Agency (PMDA) in Japan approved the iTaperloc® Complete and iG7™ Hip System, the world's first approved orthopedic implants with Iodine Technology that inhibits bacterial adhesion on the implant surface.
About this update from Zimmer Biomet Holdings, Inc.
[{"type":"text","content":"iTaperloc® Complete and iG7™ Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on the implant surface to help address the issue of Periprosthetic Joint Infection after total joint replacement","length":245,"tagName":"p","attribs":{}},{"type":"text","content":"WARSAW, Ind., Sept. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the Pharmaceutical and Medical Devices Agency (PMDA) in Japan approved the iTaperloc® Complete and iG7™ Hip System, the world's first approved orthopedic implants with Iodine Technology that inhibits bacterial adhesion on the implant surface.","length":398,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Zimmer Biomet Holdings, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Zimmer Biomet Holdings, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":101,"url":"https://media.zenfs.com/en/prnewswire.com/b2006881f7d00e48739c8660384a6286"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pmf_GsbFU_v6M8Y0pKM.1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b2006881f7d00e48739c8660384a6286","width":400,"height":101}},"href":"https://mma.prnewswire.com/media/1603977/Zimmer_Biomet_Holdings_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Implant-associated bacterial infection or Periprosthetic Joint Infection (PJI) remains one of the most common causes of revision and a challenging complication of total joint arthroplasty (TJA). PJI is estimated to occur in 1-2% of primary TJA procedures1 and can have serious consequences. In fact, the mortality rate associated with PJI approaches the 5-year mortality observed in breast cancer (11%) and far exceeds that of prostate cancer (1%).2","length":454,"tagName":"p"},{"type":"text","content":""Iodine Technology represents a significant advancement in orthopedic implant design," said Professor Hiroyuki Tsuchiya, Director at Yokohama Sakae Kyosai Hospital and Emeritus Professor of Orthopedic Surgery at Kanazawa University. Prof. Tsuchiya, who developed the technology, explained: "By integrating a controlled-release iodine layer through advanced anodization and electrophoresis, we created an...